Showing 4661-4670 of 5623 results for "".
- Katena Products Acquires Micro-Select Instrumentshttps://modernod.com/news/katena-products-acquires-micro-select-instruments/2478435/Katena Products announced the purchase of Micro-Select Instruments, a maker of ophthalmic instruments including forceps, needle holders, and speculums. Terms of the deal were not disclosed. “The acquisition of Micro-Select is an important addition to Katena’s growing instrument manu
- Innovations Will Propel OCT Market to $549 Million in Revenue in 2020https://modernod.com/news/innovations-will-propel-oct-market-to-549-million-in-revenue-in-202/2478426/Recent innovations in optical coherence tomography (OCT) technology—such as systems that are combined with fundus imagers—and software advancements, including OCT angiography, are growing in popularity. At the same time promising new technologies on the horizon, such as at-home OCT devices, are g
- Bausch Health and BHVI Announce Global Licensing Agreement For Myopia Control Contact Lenshttps://modernod.com/news/bausch-health-and-bhvi-announce-exclusive-global-licensing-agreement-for-myopia-control-contact-lens/2478422/Bausch Health has acquired an exclusive license for a myopia control contact lens design developed by BHVI, an Australian not-for-profit organization with an international focus on vision research. Terms of the deal were not disclosed. Bausch + Lomb will pair BHVI’s novel cont
- New World Medical Registers New KDB GLIDE for Smooth, Precise Goniotomyhttps://modernod.com/news/new-world-medical-registers-new-kdb-glide-for-smooth-precise-goniotomy/2478414/New World Medical announced FDA registration of the KDB GLIDE as a Class 1 device, designed to give surgeons a refined, precise experience performing excisional goniotomy for treatment of glaucoma. The KDB GLIDE device improves on the successful Kahook Dual Blade technology by adding new features
- Tepezza Data From Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)https://modernod.com/news/tepezza-data-from-phase-2-clinical-trial-evaluate-longer-term-responses-in-people-living-with-thyroid-eye-disease-ted/2478415/Horizon Therapeutics announced new long-term follow-up data from the phase 2 clinical trial of Tepezza (teprotumumab-trbw), which showed a sustained response up to 1 year following completion of treatment for Thyroid Eye Disease (TED). These data will be presented as part of the
- Will Kids Get A COVID-19 Vaccine? Pfizer To Expand Trial To Ages 12 And Uphttps://modernod.com/news/will-kids-get-a-covid-19-vaccine-pfizer-to-expand-trial-to-ages-12-and-up/2478411/Pfizer announced Monday that it has received FDA approval to enroll children as young as 12 years old in its COVID-19 vaccine trial. The expansion is aimed at understanding whether the vaccine would be safe and effective for adolescents, according to an NPR
- Outlook Therapeutics Announces Initiation of Open-Label Safety Study of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-initiation-of-open-label-safety-study-for-lytenava-for-wet-amd/2478410/Outlook Therapeutics announced the initiation and enrollment of the first patients in its planned supplemental open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD) (NORSE THREE). The open-label safety study
- Bausch Health Licenses Eyenovia’s Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12https://modernod.com/news/bausch-health-licenses-eyenovias-investigational-treatment-for-the-reduction-of-pediatric-myopia-progression-in-children-ages-3-12/2478405/Bausch Health Companies and Eyenovia announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulati
- Lilly, Incyte’s Olumiant Shows “Significant Effect” on COVID-19 Recovery Timeshttps://modernod.com/news/lilly-incytes-olumiant-shows-significant-effect-on-covid-19-recovery-times/2478401/Eli Lilly and Incyte shared more details, including mortality data, from the ongoing ACTT 2 trial evaluating their JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) in patients with COVID-19 infection. The companies said last month that the
- AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Sciencehttps://modernod.com/news/aivita-biomedicals-stem-cell-therapeutic-in-vision-loss-published-in-investigative-ophthalmology-vision-science/2478398/AIVITA Biomedical announced the publication of the peer-reviewed manuscript, “Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,” in the journal Investigative Ophthalmology & Visual Science. The